Cue biopharma reports two objective responses (1 cpr and 1upr) in first interim update from dose escalation portion of ongoing phase 1 combination study of cue-101 and keytruda® in first line patients with hpv+ recurrent/metastatic head and neck cancer

Cambridge, mass., jan. 26, 2022 (globe newswire) -- cue biopharma, inc. (nasdaq: cue), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted t cells directly within the patient's body, will provide a clinical update during today's conference call and webcast at 4:30 p.m. est. live and archived versions of the event can be accessed via the company's website.
CUE Ratings Summary
CUE Quant Ranking